Company Profile

Fresenius SE & Co. KGaA, a health care company, provides products and services for chronically ill patients in North America, Europe, the Asia-Pacific, Latin America, and Africa. It operates through Fresenius Kabi and Fresenius Helios segments. The Fresenius Kabi segment offers products for therapy and care of critically and chronically ill patients, including biopharmaceuticals, clinical nutrition, MedTech products, intravenously administered generic drugs, and IV fluids. It also provides biosimilar drugs; enteral and parenteral nutrition products; and medical technologies that include disposables, infusions pumps, apheresis machines, cell therapy devices, and other products. The Fresenius Helios segment operates hospitals, medical care centers, occupational health centers, prevention centers, and outpatient health centers, as well as provision of medical diagnostics. The company has a strategic collaboration with SAP SE and Avelios Medical GmbH for the development of a cloud-native, modular hospital information system that enables digitalization of clinical and administrative processes with AI integration. The company was formerly known as Fresenius SE and changed its name to Fresenius SE & Co. KGaA in January 2011. Fresenius SE & Co. KGaA was founded in 1912 and is based in Bad Homburg vor der Höhe, Germany.

Latest News

Rio Tinto, Western Australia Sign Agreements for Proposed Sale of Desalination Plant to Yindjibarndi WaterCo

MT Newswires • 07/27/2026

Luxfer (LXFR) Q2 Earnings: What To Expect

StockStory • 07/27/2026

SK Group, Nvidia sign $500bn deal for AI infrastructure

Verdict • 07/27/2026

Baker Hughes Q2 Adjusted Earnings Rise, Revenue Falls; Shares Up Pre-Bell

MT Newswires • 07/27/2026

LG ELECTRONICS EARNS NVIDIA AI FACTORY VALIDATION FOR ITS 600KW COOLANT DISTRIBUTION UNIT

CNW Group • 07/27/2026